Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...
An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...
Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...
In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...
Verywell Health on MSN5d
7 Medications for Dementia and Alzhiemer's DiseaseMedication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.
Clinical Trials Arena on MSN5d
Roche’s discontinued Alzheimer’s drug shows signs of preventing onsetInvestigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.
A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback